SG11202109575UA - Fused ring pyrimidone derivatives for use in the treatment of hbv infection or of hbv-induced diseases - Google Patents
Fused ring pyrimidone derivatives for use in the treatment of hbv infection or of hbv-induced diseasesInfo
- Publication number
- SG11202109575UA SG11202109575UA SG11202109575UA SG11202109575UA SG11202109575UA SG 11202109575U A SG11202109575U A SG 11202109575UA SG 11202109575U A SG11202109575U A SG 11202109575UA SG 11202109575U A SG11202109575U A SG 11202109575UA SG 11202109575U A SG11202109575U A SG 11202109575UA
- Authority
- SG
- Singapore
- Prior art keywords
- hbv
- treatment
- fused ring
- induced diseases
- pyrimidone derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19162954 | 2019-03-14 | ||
| PCT/EP2020/056884 WO2020182990A1 (en) | 2019-03-14 | 2020-03-13 | Fused ring pyrimidone derivatives for use in the treatment of hbv infection or of hbv-induced diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202109575UA true SG11202109575UA (en) | 2021-09-29 |
Family
ID=65817822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202109575UA SG11202109575UA (en) | 2019-03-14 | 2020-03-13 | Fused ring pyrimidone derivatives for use in the treatment of hbv infection or of hbv-induced diseases |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20230091047A1 (en) |
| EP (1) | EP3938362A1 (en) |
| JP (1) | JP2022524456A (en) |
| KR (1) | KR20210139319A (en) |
| CN (1) | CN113710667A (en) |
| AR (1) | AR118358A1 (en) |
| AU (1) | AU2020235270A1 (en) |
| BR (1) | BR112021017415A2 (en) |
| CA (1) | CA3132531A1 (en) |
| CL (1) | CL2021002390A1 (en) |
| CO (1) | CO2021011295A2 (en) |
| CR (1) | CR20210482A (en) |
| DO (1) | DOP2021000185A (en) |
| EA (1) | EA202192512A1 (en) |
| EC (1) | ECSP21067189A (en) |
| IL (1) | IL286210A (en) |
| JO (1) | JOP20210249A1 (en) |
| MA (1) | MA55286A (en) |
| MX (1) | MX2021011107A (en) |
| PE (1) | PE20212325A1 (en) |
| SG (1) | SG11202109575UA (en) |
| TW (1) | TW202100524A (en) |
| WO (1) | WO2020182990A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202227435A (en) * | 2020-09-11 | 2022-07-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | Fused ring pyrimidone derivatives for use in the treatment of hbv infection or of hbv-induced diseases |
| CN116724038A (en) * | 2020-10-21 | 2023-09-08 | 安力高医药股份有限公司 | Bicyclic compounds |
| WO2022266193A1 (en) * | 2021-06-18 | 2022-12-22 | Aligos Therapeutics, Inc. | Bicyclic compounds |
| US20230374008A1 (en) * | 2022-04-20 | 2023-11-23 | Aligos Therapeutics, Inc. | Bicyclic compounds |
| WO2023205653A1 (en) * | 2022-04-20 | 2023-10-26 | Aligos Therapeutics, Inc. | Bicyclic compounds |
| WO2024015425A1 (en) | 2022-07-14 | 2024-01-18 | Fmc Corporation | Herbicidal benzoxazines |
| US20240150351A1 (en) * | 2022-09-30 | 2024-05-09 | Aligos Therapeutics, Inc. | Bicyclic compounds |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2078719A4 (en) | 2006-09-28 | 2009-11-11 | Dainippon Sumitomo Pharma Co | Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the compound |
| JP2010524940A (en) * | 2007-04-20 | 2010-07-22 | シェーリング コーポレイション | Pyrimidinone derivatives and methods for their use |
| CN101854597B (en) | 2009-04-03 | 2015-06-03 | 中兴通讯股份有限公司 | Transmission method and system of large fusion IP (Internet Protocol) message |
| WO2011111880A1 (en) * | 2010-03-08 | 2011-09-15 | 주식회사 메디젠텍 | Pharmaceutical composition for treating or preventing diseases caused by the nuclear export of gsk3, including a compound for inhibiting the nuclear export of gsk3 |
| JP2012126698A (en) * | 2010-12-17 | 2012-07-05 | Tsutomu Takeuchi | Binding inhibitor of baff containing tetrahydropyridopyrimidine derivative as effective component |
| JP6713465B2 (en) * | 2014-12-30 | 2020-06-24 | ノヴィラ・セラピューティクス・インコーポレイテッド | Derivatives and methods for treating hepatitis B infection |
| CN110088104B (en) * | 2016-11-03 | 2022-04-12 | 豪夫迈·罗氏有限公司 | Tetrahydropyridopyrimidine compounds for the treatment and prevention of hepatitis B virus infection |
-
2020
- 2020-03-13 TW TW109108504A patent/TW202100524A/en unknown
- 2020-03-13 EP EP20710938.0A patent/EP3938362A1/en active Pending
- 2020-03-13 JP JP2021554985A patent/JP2022524456A/en not_active Withdrawn
- 2020-03-13 WO PCT/EP2020/056884 patent/WO2020182990A1/en active Application Filing
- 2020-03-13 CR CR20210482A patent/CR20210482A/en unknown
- 2020-03-13 MA MA055286A patent/MA55286A/en unknown
- 2020-03-13 KR KR1020217032292A patent/KR20210139319A/en unknown
- 2020-03-13 BR BR112021017415A patent/BR112021017415A2/en unknown
- 2020-03-13 MX MX2021011107A patent/MX2021011107A/en unknown
- 2020-03-13 AU AU2020235270A patent/AU2020235270A1/en not_active Abandoned
- 2020-03-13 US US17/438,767 patent/US20230091047A1/en active Pending
- 2020-03-13 CA CA3132531A patent/CA3132531A1/en active Pending
- 2020-03-13 JO JOP/2021/0249A patent/JOP20210249A1/en unknown
- 2020-03-13 EA EA202192512A patent/EA202192512A1/en unknown
- 2020-03-13 SG SG11202109575UA patent/SG11202109575UA/en unknown
- 2020-03-13 AR ARP200100713A patent/AR118358A1/en unknown
- 2020-03-13 PE PE2021001481A patent/PE20212325A1/en unknown
- 2020-03-13 CN CN202080020919.0A patent/CN113710667A/en active Pending
-
2021
- 2021-08-26 CO CONC2021/0011295A patent/CO2021011295A2/en unknown
- 2021-09-09 IL IL286210A patent/IL286210A/en unknown
- 2021-09-09 DO DO2021000185A patent/DOP2021000185A/en unknown
- 2021-09-10 EC ECSENADI202167189A patent/ECSP21067189A/en unknown
- 2021-09-13 CL CL2021002390A patent/CL2021002390A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2021002390A1 (en) | 2022-04-22 |
| EP3938362A1 (en) | 2022-01-19 |
| CN113710667A (en) | 2021-11-26 |
| AU2020235270A1 (en) | 2021-08-12 |
| ECSP21067189A (en) | 2021-11-18 |
| JP2022524456A (en) | 2022-05-02 |
| IL286210A (en) | 2021-10-31 |
| CR20210482A (en) | 2021-11-09 |
| JOP20210249A1 (en) | 2023-01-30 |
| CA3132531A1 (en) | 2020-09-17 |
| DOP2021000185A (en) | 2022-01-16 |
| MA55286A (en) | 2022-01-19 |
| PE20212325A1 (en) | 2021-12-14 |
| AR118358A1 (en) | 2021-09-29 |
| US20230091047A1 (en) | 2023-03-23 |
| BR112021017415A2 (en) | 2022-02-01 |
| TW202100524A (en) | 2021-01-01 |
| KR20210139319A (en) | 2021-11-22 |
| WO2020182990A1 (en) | 2020-09-17 |
| CO2021011295A2 (en) | 2021-09-20 |
| EA202192512A1 (en) | 2022-02-16 |
| MX2021011107A (en) | 2022-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286210A (en) | Fused ring pyrimidone derivatives for use in the treatment of hbv infection or of hbv-induced diseases | |
| IL276333B (en) | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b | |
| IL246564A (en) | 3-aryl-1-heterocyclyl-pyrazolo[3,4-d]pyrimidine derivatives and use thereof in the treatment of diseases | |
| SG11201704512PA (en) | 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection | |
| PH12015502780A1 (en) | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | |
| EP3774775C0 (en) | 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication | |
| IL276813B1 (en) | 4-SUBSTITUTED-5-AMINO-OCTAHYDROCYCLOPENTA[c]PYRROLE-5-CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMBINATIONS THEREOF AND USE THEREOF IN TREATMENT OF DISEASES | |
| UA115677C2 (en) | PYRROLO[3,2-d]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES | |
| RS62173B1 (en) | Quinoline derivatives for use in the treatment or prevention of viral infection | |
| JOP20210313A1 (en) | Fused heterocyclic derivatives | |
| IL284125A (en) | Quinoline derivatives for use in the treatment of inflammation diseases | |
| EP3471738A4 (en) | Cyclic phosphate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases | |
| EP3814326A4 (en) | Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases | |
| EP3790866A4 (en) | Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases | |
| EP4003355A4 (en) | Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases | |
| EP4003997A4 (en) | Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases | |
| EP3500578A4 (en) | Heterocycle-substituted tetracyclic compounds and methods of use thereof for the treatment of viral diseases | |
| EP3500579A4 (en) | Chromane-substituted tetracyclic compounds and uses thereof for the treatment of viral diseases | |
| EP4003987A4 (en) | Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases | |
| MX2021014581A (en) | Fused heterocyclic derivatives. | |
| MX2021014576A (en) | Fused heterocyclic derivatives as antiviral agents. | |
| EP4083044A4 (en) | Use of triazolotriazine derivative in treatment of diseases | |
| GB201817346D0 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of diseases | |
| EP3393585A4 (en) | Silane-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases | |
| TH1501007495A (en) | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases. |